Indication
Post-Essential Thrombocythemia Myelofibrosis
5 clinical trials
6 products
Clinical trial
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsStatus: Recruiting, Estimated PCD: 2024-11-30
Product
INCB057643Product
RuxolitinibClinical trial
A Multicenter, Open-Label, Phase 1 Study of AJ1-11095 Administered as Oral Monotherapy in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Status: Not yet recruiting, Estimated PCD: 2026-08-15
Product
AJ1-11095Product
MomelotinibClinical trial
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Status: Completed, Estimated PCD: 2016-09-12
Clinical trial
Phase 1b Study of PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Treated With RuxolitinibStatus: Terminated, Estimated PCD: 2022-10-19
Product
PlaceboProduct
PU-H71Clinical trial
Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential ThrombocythemiaStatus: Completed, Estimated PCD: 2018-12-06